RITUXIMAB IN RENAL ALLOGRAFT RECIPIENTS WITH EARLY ANTI-HLA ALLOANTIBODIES

利妥昔单抗在具有早期抗 HLA 同种抗体的同种异体肾移植受者中的应用

• 批准号: 7606964
• 负责人: MARTHA PAVLAKIS
• 金额: $ 0.53万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606964
• 关键词: B-Lymphocytes; Chronic; Computer Retrieval of Information on Scientific Projects Database; Effectiveness; End Point; Functional disorder; Funding; Grant; Institution; Isoantibodies; Randomized; Research; Research Personnel; Resources; Source; United States National Institutes of Health; kidney allograft; randomized placebo controlled trial; rituximab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center, single-blinded, randomized, placebo-controlled trial. Centers will screen 1200-1400 subjects and will randomize a total of 134 subjects over 3 years. The primary endpoint of this study is the effectiveness of B-cell depletion by anti-CD20 mAb therapy in reducing progression of chronic renal allograft dysfunction by chronic humoral rejection.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项多中心，单盲，随机，安慰剂对照试验。中心将筛选1200-1400名受试者，并将在3年内随机分组134名受试者。这项研究的主要终点是抗CD20 MAB治疗在慢性体液排斥下减少慢性肾脏同种异体移植功能障碍的进展。